Skip to main content

Table 3 Safety of vedolizumab, ustekinumab, and tofacitinib in patients with UC and CD refractory to anti-TNF therapy

From: Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

Variables

Vedolizumab

Ustekinumab

Tofacitinib

(n = 65, 69.2%)

(n = 16, 17.0%)

(n = 13, 13.8%)

Headache

  

1

Paraesthesia

 

1

1

Pruritus

3

  

Rash

2

  

Arthralgia

1

 

1

Herpes zoster

2

  

Flu or flu-like illness

1

1

1

Rhinitis

1

  

Oral infection

1

  

Urinary tract infection

 

1

 

Adverse event total

11 (16.9)

3 (18.8)

4 (30.8)

  1. CD, Crohn's disease; TNF, tumour necrosis factor; UC, ulcerative colitis